Clene Says Post Hoc Analyses Show CNM-Au8-Treated ALS Patients With NfL Decline Or Stabilization Had 38% Lower Risk Of Death vs. Controls In HEALEY; NDA Planned For Early Q4
Share
Why It Matters
Clene found that ALS patients taking their medicine showed less nerve damage and lived longer than patients who didn't take it. The company plans to ask the government for permission to sell the medicine soon, which is an important next step.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.